Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: Br J Haematol. 2014 May 16;166(3):311–325. doi: 10.1111/bjh.12938

Table I.

High-dose methotrexate-based trials in PCNSL that yielded median progression-free survival ≥ 2-years.

Regimen Reference Patients (n) Median PFS Median OS
MTX 2.5 g/m2, PCB, vincristine, IT-MTX, WBRT DeAngelis et al (2002) 98 24 37
MTX 8 g/m2, TMZ, rituximab, etoposide, ARA-C Wieduwilt et al (2012) 31 24 66
MTX 3.5 g/m2, rituximab, vincristine, PCB, ARA-C, rd-WBRT Morris et al (2013) 52 39 79
MTX 8 g/m2, TMZ, Ritux, Etop, ARA-C Rubenstein et al (2013b) 44 48 NR

PCNSL, primary central nervous system lymphoma; PFS, progression-free survival; OS, overall survival; MTX, methotrexate; PCB, procarbazine; IT-MTX, intrathecal methotrexate; WBRT, whole brain radiotherapy; TMZ, temozolomide; ARA-C, cytarabine; rd-WBRT, reduced dose whole brain radiotherapy. NR, not reached. (Response criteria according to Abrey et al., 2005).